ACR Convergence 2025

October 24-29, 2025. Chicago, Illinois.

View by Number View by Title View Sessions

Sunday, October 26, 2025

9:30AM-11:00AM: Plenary I (0772–0776)

10:30AM-12:30PM: (0001–0018) B Cell Biology & Targets in Autoimmune & Inflammatory Disease Poster I

10:30AM-12:30PM: (0019–0048) Genetics, Genomics & Proteomics Poster

10:30AM-12:30PM: (0049–0066) Rheumatoid Arthritis – Animal Models Poster

10:30AM-12:30PM: (0067–0097) Rheumatoid Arthritis – Etiology and Pathogenesis Poster

10:30AM-12:30PM: (0098–0114) Spondyloarthritis Including Psoriatic Arthritis – Basic Science Poster

10:30AM-12:30PM: (0115–0144) Antiphospholipid Syndrome Poster

10:30AM-12:30PM: (0145–0174) Epidemiology & Public Health Poster I

10:30AM-12:30PM: (0175–0198) Health Services Research Poster I

10:30AM-12:30PM: (0199–0209) Infection-related Rheumatic Disease Poster

10:30AM-12:30PM: (0210–0232) Measures & Measurement of Healthcare Quality Poster I

10:30AM-12:30PM: (0233–0279) Miscellaneous Rheumatic & Inflammatory Diseases Poster I

10:30AM-12:30PM: (0280–0305) Muscle Biology, Myositis & Myopathies – Basic & Clinical Science Poster I

10:30AM-12:30PM: (0306–0336) Osteoarthritis – Clinical Poster I

10:30AM-12:30PM: (0337–0356) Osteoporosis & Metabolic Bone Disease – Basic & Clinical Science Poster I

10:30AM-12:30PM: (0357–0386) Patient Outcomes, Preferences, & Attitudes Poster I

10:30AM-12:30PM: (0387–0429) Pediatric Rheumatology – Clinical Poster I

10:30AM-12:30PM: (0430–0469) Rheumatoid Arthritis – Diagnosis, Manifestations, and Outcomes Poster I

10:30AM-12:30PM: (0470–0505) Rheumatoid Arthritis – Treatment Poster I

10:30AM-12:30PM: (0506–0521) Sjögren’s Disease – Basic & Clinical Science Poster I: Etiology, Pathogenesis, Diagnosis

10:30AM-12:30PM: (0522–0553) Spondyloarthritis Including Psoriatic Arthritis – Diagnosis, Manifestations, & Outcomes Poster I

10:30AM-12:30PM: (0554–0592) Spondyloarthritis Including Psoriatic Arthritis – Treatment Poster I

10:30AM-12:30PM: (0593–0640) Systemic Lupus Erythematosus – Diagnosis, Manifestations, & Outcomes Poster I

10:30AM-12:30PM: (0641–0670) Systemic Lupus Erythematosus – Treatment Poster I

10:30AM-12:30PM: (0671–0710) Systemic Sclerosis & Related Disorders – Clinical Poster I

10:30AM-12:30PM: (0711–0730) Vasculitis – ANCA-Associated Poster I

10:30AM-12:30PM: (0731–0764) Vasculitis – Non-ANCA-Associated & Related Disorders Poster I

10:30AM-12:30PM: (0765–0771) Orthopedics, Low Back Pain, & Rehabilitation Poster

10:30AM-12:30PM: (PP01-PP08) Patient Perspectives Poster

1:00PM-2:30PM: Abstracts: Miscellaneous Rheumatic & Inflammatory Diseases I: Focus on Auto-Inflammatory Diseases (0777–0782)

1:00PM-2:30PM: Abstracts: Orthopedics, Low Back Pain, & Rehabilitation (0783–0788)

1:00PM-2:30PM: Abstracts: Patient Outcomes, Preferences, & Attitudes (0789–0794)

1:00PM-2:30PM: Abstracts: Rheumatoid Arthritis – Etiology and Pathogenesis (0795–0800)

1:00PM-2:30PM: Abstracts: Systemic Lupus Erythematosus – Treatment I (0801–0806)

1:00PM-2:30PM: Abstracts: Systemic Sclerosis & Related Disorders – Basic Science (0807–0812)

3:00PM-4:30PM: Abstracts: Pain in Rheumatic Disease Including Fibromyalgia (0813–0818)

3:00PM-4:30PM: Abstracts: Pediatric Rheumatology – Basic Science (0819–0824)

3:00PM-4:30PM: Abstracts: Professional Education (0825–0830)

3:00PM-4:30PM: Abstracts: Rheumatoid Arthritis – Diagnosis, Manifestations, and Outcomes II: Look What You Made Me Do (Prediction) (0831–0836)

3:00PM-4:30PM: Abstracts: Systemic Lupus Erythematosus – Diagnosis, Manifestations, & Outcomes I: Advances in Nephritis (0837–0842)

3:00PM-4:30PM: Abstracts: Systemic Sclerosis & Related Disorders – Clinical I (0843–0848)

Monday, October 27, 2025

8:00AM-9:30AM: Plenary II (0849–0854)

10:00AM-11:30AM: Abstracts: Antiphospholipid Syndrome (0855–0860)

10:00AM-11:30AM: Abstracts: Muscle Biology, Myositis & Myopathies – Basic & Clinical Science II: Basic & Translational Research (0861–0866)

10:00AM-11:30AM: Abstracts: Rheumatoid Arthritis – Animal Models (0867–0872)

10:00AM-11:30AM: Abstracts: Spondyloarthritis Including Psoriatic Arthritis – Treatment I: Therapies (0873–0878)

10:00AM-11:30AM: Abstracts: Systemic Sclerosis & Related Disorders – Clinical II (0879–0884)

10:00AM-11:30AM: Abstracts: T Cell Biology & Targets in Autoimmune & Inflammatory Disease (0885–0890)

10:00AM-11:30AM: Abstracts: Vasculitis – Non-ANCA-Associated & Related Disorders I: GCA From Bench to Bedside (0891–0896)

10:30AM-12:30PM: (0897–0915) B Cell Biology & Targets in Autoimmune & Inflammatory Disease Poster II

10:30AM-12:30PM: (0916–0933) Innate Immunity Poster

10:30AM-12:30PM: (0934–0954) Systemic Lupus Erythematosus – Animal Models Poster

10:30AM-12:30PM: (0955–0977) Systemic Sclerosis & Related Disorders – Basic Science Poster I

10:30AM-12:30PM: (0978–1006) T Cell Biology & Targets in Autoimmune & Inflammatory Disease Poster

10:30AM-12:30PM: (1007–1037) Epidemiology & Public Health Poster II

10:30AM-12:30PM: (1038–1054) Health Services Research Poster II

10:30AM-12:30PM: (1055–1087) Healthcare Disparities in Rheumatology Posters

10:30AM-12:30PM: (1088–1122) Immunological Complications of Medical Therapy Poster

10:30AM-12:30PM: (1123–1146) Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster I

10:30AM-12:30PM: (1147–1190) Miscellaneous Rheumatic & Inflammatory Diseases Poster II

10:30AM-12:30PM: (1191–1220) Muscle Biology, Myositis & Myopathies – Basic & Clinical Science Poster II

10:30AM-12:30PM: (1221–1247) Pain in Rheumatic Disease Including Fibromyalgia Poster

10:30AM-12:30PM: (1248–1271) Patient Outcomes, Preferences, & Attitudes Poster II

10:30AM-12:30PM: (1272–1305) Pediatric Rheumatology – Clinical Poster II

10:30AM-12:30PM: (1306–1346) Rheumatoid Arthritis – Diagnosis, Manifestations, and Outcomes Poster II

10:30AM-12:30PM: (1347–1375) Rheumatoid Arthritis – Treatment Poster II

10:30AM-12:30PM: (1376–1404) Sjögren’s Disease – Basic & Clinical Science Poster II: Clinical Manifestations and Health Outcomes

10:30AM-12:30PM: (1405–1433) Spondyloarthritis Including Psoriatic Arthritis – Diagnosis, Manifestations, & Outcomes Poster II

10:30AM-12:30PM: (1434–1466) Spondyloarthritis Including Psoriatic Arthritis – Treatment Poster II

10:30AM-12:30PM: (1467–1516) Systemic Lupus Erythematosus – Diagnosis, Manifestations, & Outcomes Poster II

10:30AM-12:30PM: (1517–1552) Systemic Lupus Erythematosus – Treatment Poster II

10:30AM-12:30PM: (1553–1591) Systemic Sclerosis & Related Disorders – Clinical Poster II

10:30AM-12:30PM: (1592–1611) Vasculitis – ANCA-Associated Poster II

10:30AM-12:30PM: (1612–1632) Vasculitis – Non-ANCA-Associated & Related Disorders Poster II

10:30AM-12:30PM: (1633–1649) ARP Posters II: ARP Epidemiology & Public Health

1:00PM-2:30PM: Abstracts: Cytokines & Cell Trafficking (1650–1655)

1:00PM-2:30PM: Abstracts: Health Services Research (1656–1661)

1:00PM-2:30PM: Abstracts: Miscellaneous Rheumatic & Inflammatory Diseases II: Models and Mechanisms (1662–1667)

1:00PM-2:30PM: Abstracts: Pediatric Rheumatology – Clinical I (1668–1673)

1:00PM-2:30PM: Abstracts: Rheumatoid Arthritis – Treatment I: Preventative and Novel Treatments (1674–1679)

1:00PM-2:30PM: Abstracts: Sjögren’s Disease – Basic & Clinical Science (1680–1685)

3:00PM-4:30PM: Abstracts: ARP I: Multidimensional Influences on Health in SLE (1686–1691)

3:00PM-4:30PM: Abstracts: B Cell Biology & Targets in Autoimmune & Inflammatory Disease (1691–1697)

3:00PM-4:30PM: Abstracts: Genetics, Genomics & Proteomics (1698–1703)

3:00PM-4:30PM: Abstracts: Healthcare Disparities in Rheumatology (1704–1709)

3:00PM-4:30PM: Abstracts: Spondyloarthritis Including Psoriatic Arthritis – Diagnosis, Manifestations, & Outcomes I: Advances in Psoriatic Disease (1710–1715)

3:00PM-4:30PM: Abstracts: Systemic Lupus Erythematosus – Diagnosis, Manifestations, & Outcomes II: Morbidity & Mortality (1716–1721)

Tuesday, October 28, 2025

8:00AM-9:30AM: Plenary III (1722–1727)

8:15AM-9:30AM: (PP09-PP13) Patient Perspectives

10:00AM-11:30AM: Abstracts: Immunological Complications of Medical Therapy (1728–1733)

10:00AM-11:30AM: Abstracts: Osteoarthritis & Joint Biology – Basic Science (1734–1739)

10:00AM-11:30AM: Abstracts: Pediatric Rheumatology – Clinical II (1740–1745)

10:00AM-11:30AM: Abstracts: Rheumatoid Arthritis – Diagnosis, Manifestations, and Outcomes I: Breathe (ILD/Pulmonary) (1746–1751)

10:00AM-11:30AM: Abstracts: Spondyloarthritis Including Psoriatic Arthritis – Basic Science (1752–1757)

10:00AM-11:30AM: Abstracts: Systemic Lupus Erythematosus – Animal Models (1758–1763)

10:00AM-11:30AM: Abstracts: Vasculitis – ANCA-Associated (1764–1769)

10:30AM-12:30PM: (1770–1779) Cytokines & Cell Trafficking Poster

10:30AM-12:30PM: (1780–1808) Osteoarthritis & Joint Biology – Basic Science Poster

10:30AM-12:30PM: (1809–1829) Pediatric Rheumatology – Basic Science Poster

10:30AM-12:30PM: (1830–1854) Systemic Lupus Erythematosus – Etiology and Pathogenesis Poster

10:30AM-12:30PM: (1855–1876) Systemic Sclerosis & Related Disorders – Basic Science Poster II

10:30AM-12:30PM: (1877–1913) Epidemiology & Public Health Poster III

10:30AM-12:30PM: (1914–1935) Health Services Research Poster III

10:30AM-12:30PM: (1936–1971) Imaging of Rheumatic Diseases Poster

10:30AM-12:30PM: (1972–1989) Measures & Measurement of Healthcare Quality Poster II

10:30AM-12:30PM: (1990–2014) Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster II

10:30AM-12:30PM: (2015–2051) Miscellaneous Rheumatic & Inflammatory Diseases Poster III

10:30AM-12:30PM: (2052–2078) Muscle Biology, Myositis & Myopathies – Basic & Clinical Science Poster III

10:30AM-12:30PM: (2079–2105) Osteoarthritis – Clinical Poster II

10:30AM-12:30PM: (2106–2123) Osteoporosis & Metabolic Bone Disease – Basic & Clinical Science Poster II

10:30AM-12:30PM: (2124–2158) Pediatric Rheumatology – Clinical Poster III

10:30AM-12:30PM: (2159–2194) Professional Education Poster

10:30AM-12:30PM: (2195–2226) Reproductive Issues in Rheumatic Disorders Posters

10:30AM-12:30PM: (2227–2264) Rheumatoid Arthritis – Diagnosis, Manifestations, and Outcomes Poster III

10:30AM-12:30PM: (2265–2289) Rheumatoid Arthritis – Treatment Poster III

10:30AM-12:30PM: (2290–2304) Sjögren’s Disease – Basic & Clinical Science Poster III: Treatment and Trial Outcome Measures

10:30AM-12:30PM: (2305–2337) Spondyloarthritis Including Psoriatic Arthritis – Diagnosis, Manifestations, & Outcomes Poster III

10:30AM-12:30PM: (2338–2376) Spondyloarthritis Including Psoriatic Arthritis – Treatment Poster III

10:30AM-12:30PM: (2377–2436) Systemic Lupus Erythematosus – Diagnosis, Manifestations, & Outcomes Poster III

10:30AM-12:30PM: (2437–2469) Systemic Lupus Erythematosus – Treatment Poster III

10:30AM-12:30PM: (2470–2503) Systemic Sclerosis & Related Disorders – Clinical Poster III

10:30AM-12:30PM: (2504–2523) Vasculitis – ANCA-Associated Poster III

10:30AM-12:30PM: (2524–2546) Vasculitis – Non-ANCA-Associated & Related Disorders Poster III

10:30AM-12:30PM: (2547–2566) ARP Posters I

1:00PM-2:30PM: Abstracts: Epidemiology & Public Health II (2567–2572)

1:00PM-2:30PM: Abstracts: Infection-related Rheumatic Disease (2573–2578)

1:00PM-2:30PM: Abstracts: Innate Immunity (2579–2584)

1:00PM-2:30PM: Abstracts: Metabolic & Crystal Arthropathies – Basic & Clinical Science (2585–2590)

1:00PM-2:30PM: Abstracts: Osteoporosis & Metabolic Bone Disease – Basic & Clinical Science (2591–2596)

1:00PM-2:30PM: Abstracts: Systemic Lupus Erythematosus – Etiology and Pathogenesis (2597–2602)

3:00PM-4:30PM: Abstracts: ARP II: Perception, Prediction, and Prevention (2603–2608)

3:00PM-4:30PM: Abstracts: Imaging of Rheumatic Diseases (2609–2614)

3:00PM-4:30PM: Abstracts: Measures & Measurement of Healthcare Quality (2615–2620)

3:00PM-4:30PM: Abstracts: Osteoarthritis – Clinical (2621–2626)

3:00PM-4:30PM: Abstracts: Reproductive Issues in Rheumatic Disorders (2627–2632)

3:00PM-4:30PM: Abstracts: Spondyloarthritis Including Psoriatic Arthritis – Diagnosis, Manifestations, & Outcomes II: Advances in Axial Spondyloarthritis (2633–2638)

Wednesday, October 29, 2025

9:30AM-11:00AM: Abstracts: Rheumatoid Arthritis – Treatment II: Phenotyping and Personalization (2639–2644)

9:30AM-11:00AM: Abstracts: Systemic Lupus Erythematosus – Diagnosis, Manifestations, & Outcomes III (2645–2650)

9:30AM-11:00AM: Abstracts: Systemic Sclerosis & Related Disorders – Clinical III (2651–2656)

11:30AM-1:00PM: Abstracts: Epidemiology & Public Health I (2657–2662)

11:30AM-1:00PM: Abstracts: Miscellaneous Rheumatic & Inflammatory Diseases III: End Organ Focus on Heart, Lung and Eye (2663–2668)

11:30AM-1:00PM: Abstracts: Muscle Biology, Myositis & Myopathies – Basic & Clinical Science I: Diagnostics & Therapeutics (2669–2674)

11:30AM-1:00PM: Abstracts: Pediatric Rheumatology – Clinical III (2675–2680)

11:30AM-1:00PM: Abstracts: Rheumatoid Arthritis – Diagnosis, Manifestations, and Outcomes III: Long Live (Comorbidity and Outcomes) (2681–2686)

11:30AM-1:00PM: Abstracts: Spondyloarthritis Including Psoriatic Arthritis – Treatment II: Pathogenesis, Exercise, and Dietary Interventions (2687–2692)

11:30AM-1:00PM: Abstracts: Systemic Lupus Erythematosus – Treatment II (2693–2698)

11:30AM-1:00PM: Abstracts: Vasculitis – Non-ANCA-Associated & Related Disorders II (2699–2704)

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].